Hayes-Larson Eleanor, Hirsch-Moverman Yael, Saito Suzue, Frederix Koen, Pitt Blanche, Maama Bridget Llang, Howard Andrea A
a ICAP, Mailman School of Public Health, Columbia University , New York , NY , USA.
b Department of Epidemiology , Mailman School of Public Health, Columbia University , New York , NY , USA.
AIDS Care. 2017 Aug;29(8):978-984. doi: 10.1080/09540121.2017.1280124. Epub 2017 Jan 18.
Disclosure of HIV-positive status has important implications for patient outcomes and preventing HIV transmission, but has been understudied in TB-HIV patients. We assessed disclosure patterns and correlates of non-disclosure among adult TB-HIV patients initiating ART enrolled in the START Study, a mixed-methods cluster-randomized trial conducted in Lesotho, which evaluated a combination intervention package (CIP) versus standard of care. Interviewer-administered questionnaire data were analyzed to describe patterns of disclosure. Patient-related factors were assessed for association with non-disclosure to anyone other than a health-care provider and primary partners using generalized linear mixed models. Among 371 participants, 95% had disclosed their HIV diagnosis to someone other than a health-care provider, most commonly a spouse/primary partner (76%). Age, TB knowledge, not planning to disclose TB status, greater perceived TB stigma, and CIP were associated with non-disclosure in unadjusted models (p < .1). In adjusted models, all point estimates were similar and greater TB knowledge (adjusted odds ratio [aOR] 0.59, 95% confidence interval [CI] 0.39-0.90) and CIP (aOR 0.20, 95% CI 0.05-0.79) remained statistically significant. Among 220 participants with a primary partner, 76% had disclosed to that partner. Significant correlates of partner non-disclosure (p < .1) in unadjusted analyses included being female, married/cohabitating, electricity at home, not knowing if partner was HIV-positive, and TB knowledge. Adjusted point estimates were largely similar, and being married/cohabitating (aOR 0.03, 95% CI 0.01-0.12), having electricity at home (aOR 0.38, 95% CI 0.17-0.85) and greater TB knowledge (aOR 0.76, 95% CI 0.59-0.98) remained significant. In conclusion, although nearly all participants reported disclosing their HIV status to someone other than a health-care provider at ART initiation, nearly a quarter of participants with a primary partner had not disclosed to their partner. Additional efforts to support HIV disclosure (e.g., counseling) may be needed for TB-HIV patients, particularly for women and those unaware of their partners' status.
披露艾滋病毒阳性状况对患者的治疗结果和预防艾滋病毒传播具有重要意义,但在结核病合并艾滋病毒患者中尚未得到充分研究。我们评估了参与“启动研究”(START Study)的成年结核病合并艾滋病毒患者在开始接受抗逆转录病毒治疗(ART)时的披露模式及未披露的相关因素。“启动研究”是在莱索托进行的一项混合方法整群随机试验,比较了联合干预方案(CIP)与标准治疗。对由访谈员实施的问卷调查数据进行分析以描述披露模式。使用广义线性混合模型评估与未向医疗保健提供者和主要伴侣之外的任何人披露信息相关的患者因素。在371名参与者中,95%已向医疗保健提供者之外的其他人披露了他们的艾滋病毒诊断情况,最常见的是向配偶/主要伴侣披露(76%)。在未调整的模型中,年龄、结核病知识、不打算披露结核病状况、更高的结核病耻辱感认知以及联合干预方案与未披露信息相关(p < 0.1)。在调整后的模型中,所有点估计值相似,更高的结核病知识(调整后的优势比[aOR] 0.59,95%置信区间[CI] 0.39 - 0.90)和联合干预方案(aOR 0.20,95% CI 0.05 - 0.79)仍具有统计学意义。在220名有主要伴侣的参与者中,76%已向该伴侣披露。在未调整分析中,与未向伴侣披露信息显著相关(p < 0.1)的因素包括女性、已婚/同居、家中有电、不知道伴侣是否为艾滋病毒阳性以及结核病知识。调整后的点估计值大致相似,已婚/同居(aOR 0.03,95% CI 0.01 - 0.12)、家中有电(aOR 0.38,95% CI 0.17 - 0.85)以及更高的结核病知识(aOR 0.76,95% CI 0.59 - 0.98)仍具有显著性。总之,尽管几乎所有参与者报告在开始接受抗逆转录病毒治疗时已向医疗保健提供者之外的其他人披露了他们的艾滋病毒状况,但近四分之一有主要伴侣的参与者未向其伴侣披露。可能需要额外的努力来支持结核病合并艾滋病毒患者披露艾滋病毒信息(例如咨询),特别是对于女性和那些不知道其伴侣状况的人。